Top 16 Companies in Animal Health Market| Market Reports World

Animal Health Market Overview

According to recent research conducted by Market Reports World,The global Animal Health size is forecasted to reach USD 64644.1 Million by 2026 from USD 98635.2 Million in 2035, growing at a steady CAGR of 4.8% during the forecast from 2026 to 2035.

The animal health market supports disease prevention, diagnosis, treatment, nutrition, productivity, and welfare across companion animals and livestock. Global demand is influenced by approximately 1.5 billion cattle, more than 1 billion sheep, nearly 1 billion goats, and an expanding poultry population exceeding 26 billion birds. The sector includes vaccines, pharmaceuticals, medicinal feed additives, diagnostics, digital monitoring systems, and veterinary services. Companion-animal care is gaining importance as dog and cat ownership expands, while livestock health remains essential for food security. Zoonotic disease control is another priority because approximately 60% of recognized infectious diseases can pass between animals and humans.

Navigate Market Opportunities with Data-Driven Business Intelligence: Market Reports World

Animal health market intelligence helps manufacturers, investors, distributors, and veterinary organizations evaluate demand across more than 100 national markets. Data-driven analysis can compare vaccine adoption, livestock density, pet ownership, veterinary infrastructure, regulatory approvals, disease prevalence, and competitive positioning. Business intelligence also supports portfolio decisions across pharmaceuticals, diagnostics, feed additives, parasiticides, and biological products. Companies can identify opportunities by assessing more than 20 animal categories, 5 principal product groups, and several distribution channels. Market reports help decision-makers examine production capacity, regional demand, patent activity, product launches, and company expansion strategies while managing regulatory, supply-chain, and commercialization risks within the animal health market.

Top 5 Trends in the Animal Health Market

Increasing Adoption of Preventive Vaccination

Preventive vaccination is becoming one of the strongest animal health market trends as governments, producers, and pet owners attempt to reduce treatment costs and disease-related losses. Vaccination programs address more than 20 major livestock and companion-animal diseases, including rabies, foot-and-mouth disease, avian influenza, Newcastle disease, canine parvovirus, and feline viral infections. Rabies causes approximately 59,000 human deaths annually, with dogs responsible for nearly 99% of human transmission cases. This burden is encouraging wider canine immunization. Poultry producers are also adopting automated hatchery vaccination technologies capable of treating thousands of birds per hour. Vaccine manufacturers are investing in recombinant, vector-based, multivalent, and thermostable products that can improve protection, reduce handling requirements, and support mass administration. The growing emphasis on preventive care is strengthening demand for veterinary vaccines, cold-chain systems, vaccination equipment, traceability platforms, and field surveillance services across the animal health market.

Expansion of Companion-Animal Healthcare

Companion-animal healthcare is expanding as pets increasingly receive medical attention comparable to human family members. The United States has approximately 89 million pet dogs and more than 73 million pet cats, creating substantial demand for vaccines, dermatology treatments, pain-management products, parasiticides, dental care, nutritional products, and diagnostic testing. European households collectively keep more than 340 million companion animals, including dogs, cats, birds, small mammals, fish, and reptiles. Longer pet lifespans are increasing the incidence of osteoarthritis, diabetes, cancer, cardiovascular disorders, kidney disease, and cognitive decline. Veterinary clinics are consequently adopting advanced imaging, hematology analyzers, molecular diagnostics, and point-of-care testing. Companies are expanding portfolios through monoclonal antibodies, extended-duration parasiticides, dermatological therapies, and specialty nutrition. This trend is shifting animal health market competition toward innovation, convenience, treatment adherence, and measurable improvements in pet quality of life.

Growth of Veterinary Diagnostics and Digital Monitoring

Veterinary diagnostics and digital monitoring are transforming disease detection and animal-management practices. Modern point-of-care analyzers can provide hematology, blood chemistry, immunoassay, and urinalysis results within 15 minutes, enabling faster clinical decisions. Livestock farms are adopting electronic identification tags, connected collars, rumination monitors, temperature sensors, automated weighing platforms, and artificial-intelligence systems. A single connected dairy sensor may collect more than 1 million data points during its operating life, helping identify changes in activity, feeding, estrus, and health. Molecular tests are improving the detection of pathogens before visible symptoms become severe. Cloud-connected systems also allow veterinarians to compare patient records across multiple clinics. These technologies strengthen preventive care, reduce diagnostic delays, improve herd productivity, and create recurring demand for test consumables, software subscriptions, monitoring equipment, and data-management services throughout the animal health market.

Reduced Dependence on Routine Antibiotics

Antimicrobial resistance is encouraging livestock producers and veterinary professionals to reduce unnecessary antibiotic use. Drug-resistant infections are associated with more than 1 million direct human deaths annually, while resistant organisms can circulate among people, animals, food systems, and the environment. Regulators in several markets have restricted routine antibiotic growth promotion and strengthened veterinary oversight for medically important antimicrobials. Producers are responding through vaccination, probiotics, prebiotics, enzymes, biosecurity, improved housing, genetic selection, and precision nutrition. Poultry and swine operations are also using diagnostic tests to distinguish bacterial infections from other health conditions before treatment. Animal health companies are developing alternatives that support immunity, intestinal health, and disease prevention without continuous antibiotic administration. This transition is creating product-development opportunities while requiring manufacturers to demonstrate safety, consistency, field performance, and compatibility with modern livestock-production systems.

One Health and Zoonotic Disease Preparedness

The One Health approach recognizes that human, animal, and environmental health are interconnected. Approximately 75% of emerging infectious diseases have an animal origin, making veterinary surveillance essential for public-health preparedness. Governments and animal health companies are strengthening monitoring for avian influenza, African swine fever, rabies, brucellosis, coronaviruses, and vector-borne diseases. More than 50 animal species can participate in the ecology of important zoonotic pathogens, requiring collaboration among veterinarians, physicians, laboratories, wildlife authorities, and food producers. Companies are investing in rapid diagnostic tests, vaccine platforms, genomic surveillance, cold-chain capacity, and outbreak-response manufacturing. Climate-related changes in mosquito and tick distribution are also increasing attention to parasitic and vector-borne conditions. One Health programs create animal health market opportunities in disease mapping, laboratory networks, preventive vaccination, biosecurity consulting, and integrated digital surveillance.

Regional Growth and Demand

North America

North America represents a highly developed animal health market supported by advanced veterinary infrastructure, strong pet ownership, commercial livestock production, and substantial research activity. The United States has more than 120,000 veterinarians, while Canada has over 15,000 veterinarians serving companion animals, livestock, equine practices, public health, research, and food inspection. Approximately 66% of United States households own at least 1 pet, supporting demand for vaccines, parasiticides, dermatology products, pain therapies, diagnostics, and specialty medicines. Preventive care is becoming more sophisticated as veterinary clinics introduce digital radiography, ultrasound, in-house laboratories, molecular testing, and cloud-based patient management.

Livestock health is equally important because the United States maintains more than 87 million cattle and calves, approximately 74 million hogs, and commercial poultry flocks containing billions of birds during an annual production cycle. Large production systems require systematic vaccination, nutritional health products, reproductive management, electronic identification, and disease surveillance. Outbreak concerns involving avian influenza and other transboundary diseases are increasing demand for laboratory testing and farm biosecurity. North American companies are developing monoclonal antibodies, long-acting parasiticides, precision livestock technologies, and connected diagnostic platforms. The region also has more than 30 veterinary medical colleges, supporting clinical research and professional training. Regulatory scrutiny remains high, encouraging manufacturers to maintain rigorous pharmacovigilance, manufacturing quality, efficacy documentation, and antimicrobial-stewardship programs.

Europe

Europe has a diverse animal health market characterized by extensive companion-animal ownership, modern livestock systems, strict welfare standards, and coordinated disease-control programs. European households keep approximately 127 million cats and 104 million dogs, alongside millions of birds, fish, reptiles, and small mammals. This population supports demand for preventive vaccines, anti-infectives, parasiticides, dermatology treatments, dental products, behavioral therapies, and advanced diagnostics. Countries such as Germany, France, the United Kingdom, Italy, Spain, and the Netherlands maintain mature veterinary networks. The region also hosts several major animal health companies, including operations headquartered in France, Germany, and the United Kingdom.

Europe’s livestock sector includes more than 70 million cattle, approximately 130 million pigs, and over 70 million sheep. Animal disease prevention is closely connected to food safety, traceability, export protection, and antimicrobial stewardship. Regulations implemented across 27 European Union member states have increased oversight of veterinary medicines and medicated feed. This has accelerated demand for vaccines, diagnostics, probiotics, biosecurity solutions, and precision-farming technologies. Electronic livestock identification and farm-management platforms help monitor health, movement, reproduction, and treatment history. European manufacturers are also developing products for aquaculture, equine medicine, and specialty companion-animal care. Market challenges include regulatory complexity, veterinary workforce shortages, pricing pressure, and the cost of maintaining compliant manufacturing across multiple jurisdictions and languages.

Asia-Pacific

Asia-Pacific is an important animal health market because it contains the world’s largest livestock populations and a rapidly expanding companion-animal sector. India maintains more than 300 million cattle and buffalo, while China accounts for a substantial share of global pig and poultry production. The region also contains more than 60% of the global population, increasing demand for safe animal protein, disease control, and sustainable livestock productivity. Veterinary vaccines, feed additives, anti-infectives, parasiticides, fertility products, and nutritional supplements are widely used across dairy, poultry, swine, aquaculture, and small-ruminant production systems.

Urbanization is supporting pet ownership in China, India, Japan, South Korea, Australia, and Southeast Asia. Large cities are recording stronger demand for companion-animal vaccination, diagnostics, surgery, dermatology, and premium preventive products. Asia-Pacific is also responsible for more than 85% of global aquaculture production, generating demand for fish vaccines, water-quality monitoring, probiotics, and disease diagnostics. Governments are strengthening surveillance for African swine fever, avian influenza, rabies, and foot-and-mouth disease. However, veterinary access remains uneven, especially in rural areas where 1 veterinarian may serve thousands of animals. Market opportunities include affordable vaccines, mobile veterinary clinics, temperature-stable medicines, telemedicine, local manufacturing, and digital platforms designed for small farms. Competitive success depends on distribution reach, product affordability, disease-specific portfolios, and reliable field support.

Middle East & Africa

The Middle East and Africa animal health market is influenced by large cattle, sheep, goat, camel, and poultry populations. Africa holds more than 360 million cattle, over 400 million goats, and approximately 430 million sheep, making livestock health central to household income, nutrition, trade, and rural employment. The Middle East also maintains intensive dairy and poultry operations that require vaccines, biosecurity, reproductive management, and nutritional health products. Demand is particularly strong for products addressing foot-and-mouth disease, peste des petits ruminants, brucellosis, lumpy skin disease, internal parasites, and tick-borne infections.

Veterinary infrastructure varies considerably across more than 70 countries within the combined region. Some markets operate advanced commercial farms and specialist veterinary hospitals, while remote communities depend on public programs, mobile services, and community animal-health workers. Rabies remains a serious concern, and limited canine vaccination coverage contributes to preventable transmission. Temperature conditions exceeding 40°C in several locations create cold-chain and storage challenges for vaccines and biological products. Manufacturers are consequently developing thermostable formulations, smaller pack sizes, and simplified administration systems. Growing poultry consumption, dairy investment, pet ownership, and government vaccination campaigns provide opportunities for animal health companies. Constraints include counterfeit medicines, limited laboratory capacity, import dependence, affordability concerns, and shortages of trained veterinary professionals.

Top Companies in the Animal Health Market

• Bayer Animal Health
• Ceva Animal Healthcare
• Elanco Animal Health Inc.
• Merck Ltd.
• Merial (Animal Health division of Sanofi)
• Zoetis Animal Healthcare
• Pfizer
• Vétoquinol SA
• Sanofi-Aventis
• Dechra Pharmaceuticals Plc
• Virbac
• Novartis
• C. H. Boehringer Sohn AG & Co. KG
• Heska Corporation
• Bioniche Animal Health Canada, Inc.
• Cadila Healthcare Ltd.

Top Companies Profile and Overview

Bayer Animal Health

Headquarters: Legacy animal health

operations were managed from Monheim, Germany. Bayer Animal Health developed veterinary medicines for companion animals and livestock, with recognized capabilities in parasiticides, anti-infectives, and farm-animal health. Its portfolio included products serving dogs, cats, cattle, and other species across more than 90 markets. Bayer agreed to divest the animal health business in 2019, and Elanco completed the acquisition in August 2020. Consequently, Bayer Animal Health no longer operates as an independent competitor in the current animal health market. Its former brands, commercial teams, manufacturing assets, and research capabilities were largely integrated into Elanco. The transaction strengthened Elanco’s position in companion-animal parasiticides and expanded its geographic distribution, particularly through established retail and veterinary channels.

Ceva Animal Healthcare

Headquarters: Libourne, France. Ceva Animal Healthcare

formally Ceva Santé Animale, was established in 1999 and has developed into a major global veterinary company. It employs more than 7,000 people in 47 countries and operates 21 research centers and 32 production sites. Ceva serves poultry, swine, ruminants, and companion animals through vaccines, pharmaceutical products, welfare solutions, equipment, and technical services. Its poultry business combines hatchery vaccination equipment with vaccines and implementation support. The company also has recognized capabilities in animal behavior, cardiology, reproduction, dermatology, and infectious-disease prevention. Ceva’s market strategy emphasizes preventive medicine and the One Health relationship linking animals, people, and ecosystems. Its international manufacturing structure supports both mature and emerging animal health markets.

Elanco Animal Health Inc.

Headquarters: Indianapolis, Indiana, United States. Elanco traces its animal health

history to 1954 and became an independent publicly traded company after separating from Eli Lilly in 2018. It serves companion animals and farm animals with parasiticides, vaccines, therapeutic medicines, enzymes, nutritional products, and disease-prevention solutions. Elanco acquired Novartis Animal Health in 2015 and Bayer Animal Health in 2020, significantly expanding its international scale and product portfolio. The company markets products across more than 90 countries and supports dogs, cats, cattle, poultry, swine, sheep, and aquaculture. Elanco’s competitive priorities include pet therapeutics, livestock sustainability, intestinal health, parasiticides, and alternatives to routine antibiotics. Its broad portfolio provides access to veterinary clinics, farms, distributors, pharmacies, and retail channels.

Merck Ltd.

Headquarters: Rahway, New Jersey, United States. Merck’s

animal health division operates as Merck Animal Health in the United States and Canada and as MSD Animal Health in many international markets. The division maintains offices in more than 50 countries and makes products available across approximately 150 markets. Its portfolio includes vaccines, pharmaceuticals, parasiticides, animal-identification technologies, digital monitoring systems, and veterinary services. Merck serves companion animals, cattle, poultry, swine, horses, aquaculture, and other production species. The company has more than 100 years of experience in animal health-related scientific development. Strategic strengths include livestock monitoring, connected identification, vaccine manufacturing, and companion-animal parasiticides. Research investments focus on preventing infectious diseases, improving productivity, supporting traceability, and enabling earlier clinical intervention.

Merial (Animal Health Division of Sanofi)

Headquarters: Lyon, France, before integration. Merial

was formed in 1997 through the combination of animal health operations associated with Merck and Rhône-Mérieux. It later became the animal health division of Sanofi and developed vaccines, parasiticides, anti-infectives, and therapeutic products sold across more than 150 countries. Its historical portfolio included widely recognized products for dogs, cats, cattle, poultry, and other species. Merial employed approximately 6,900 people before its transfer. A business exchange between Sanofi and Boehringer Ingelheim closed in 2017, after which Merial was integrated into Boehringer Ingelheim Animal Health. Merial therefore no longer operates as an independent animal health company, although several former Merial brands, technologies, manufacturing facilities, and research programs remain commercially important under Boehringer Ingelheim.

Zoetis Animal Healthcare

Headquarters: Parsippany, New Jersey, United States.

Zoetis has a heritage extending more than 70 years and operates in over 100 countries. The company emerged from Pfizer’s former animal health business and became fully independent following its 2013 public listing and subsequent separation. Zoetis provides vaccines, anti-infectives, parasiticides, dermatology treatments, pain-management products, genetic services, diagnostics, and livestock medicines. Its portfolio supports 8 major animal species, including dogs, cats, cattle, swine, poultry, horses, sheep, and fish. Zoetis has expanded into point-of-care diagnostics, reference laboratory services, monoclonal antibodies, and pet genetics. Its scale, veterinary relationships, manufacturing network, and research investment make it one of the most influential companies shaping innovation and competition in the animal health market.

Pfizer

Headquarters: New York City, United States. Pfizer

played an important historical role in the animal health market after entering veterinary medicine through antibiotic research in the 1950s. Its animal health division developed vaccines, pharmaceuticals, parasiticides, and livestock productivity products over approximately 60 years. Pfizer separated the business under the Zoetis name, completed an initial public offering in 2013, and subsequently distributed its remaining ownership to Pfizer shareholders. Pfizer therefore does not currently operate the former global animal health portfolio as a direct business division. Its inclusion among top animal health companies primarily reflects its historical contribution and the scientific platform from which Zoetis developed. Many products, researchers, commercial relationships, and manufacturing capabilities associated with Pfizer Animal Health continued within Zoetis after the separation.

Vétoquinol SA

Headquarters: Lure, France. Vétoquinol

was founded in 1933 and remains an independent, family-controlled company dedicated to animal health. It employs approximately 2,500 people across 24 countries, while distribution partnerships provide product access in more than 80 countries. The company serves companion animals and livestock through anti-infectives, pain and inflammation products, cardio-nephrology treatments, dermatology solutions, reproductive medicines, and nutritional products. Vétoquinol concentrates on selected therapeutic categories where veterinary specialization and brand development can create long-term value. Its international network combines direct subsidiaries in strategic markets with local distribution partners elsewhere. The company’s exclusive focus on veterinary health supports targeted research, regulatory expertise, practitioner education, and portfolio management across different animal species and national treatment environments.

Sanofi-Aventis

Headquarters: Paris, France. Sanofi-Aventis,

now known as Sanofi, previously participated directly in the animal health market through Merial. Sanofi gained full control of Merial in 2009 after acquiring Merck’s interest in the joint venture. Merial subsequently operated as a large global veterinary business with vaccines, parasiticides, therapeutic medicines, and biological products for companion animals and livestock. In 2017, Sanofi transferred Merial to Boehringer Ingelheim as part of a strategic business exchange. Sanofi therefore no longer competes directly through a major standalone animal health division. Its historical importance remains significant because Merial contributed several established veterinary brands, vaccine technologies, manufacturing facilities, and research platforms. Those operations now form an important part of Boehringer Ingelheim’s animal health portfolio.

Dechra Pharmaceuticals Plc

Headquarters: Boston, Massachusetts, United States.

Dechra opened its new global headquarters in Boston in June 2026 after historically managing its global operations from the United Kingdom. The company specializes exclusively in veterinary pharmaceuticals and related products. It has operations in 27 countries, employs more than 2,700 people, and reaches additional markets through distributors and commercial partners. Dechra focuses on specialist categories such as endocrinology, anesthesia, analgesia, dermatology, equine medicine, nutrition, and antimicrobial therapy. Its principal customers are veterinarians, giving the company a focused professional channel. Dechra has expanded through internal product development, licensing, and acquisitions. Its strategy emphasizes specialized treatments for clinical conditions that may receive less attention from diversified pharmaceutical manufacturers, supporting differentiation within the animal health market.

Virbac

Headquarters: Carros, France. Virbac

was founded by a veterinarian in 1968 and is dedicated exclusively to animal health. The company serves veterinarians, farmers, and pet owners in more than 100 countries through approximately 36 sales subsidiaries. Its manufacturing network operates across 10 countries, while research centers support development in several international locations. Virbac provides vaccines, antibiotics, parasiticides, dermatology treatments, dental-care products, nutrition, diagnostics, reproductive products, aquaculture solutions, and electronic identification tools. Its portfolio covers more than 50 animal species and addresses both companion-animal and food-producing-animal needs. The company’s veterinary heritage supports practical product development, while its balanced geographic presence reduces dependence on 1 market. Virbac competes through specialization, localized portfolios, and close relationships with veterinary professionals.

Novartis

Headquarters: Basel, Switzerland. Novartis

previously operated an international animal health business offering medicines and vaccines for companion animals, livestock, and aquaculture. The division developed capabilities in parasiticides, anti-infectives, dermatology, pain management, and farm-animal health. In 2014, Novartis agreed to sell the business to Eli Lilly, and the transaction closed on January 1, 2015. The acquired operations were integrated into Elanco, expanding Elanco’s product portfolio and position in the United States, Europe, and other international markets. Novartis is therefore a legacy participant rather than an active standalone competitor in today’s animal health market. Its former veterinary products, scientific expertise, regulatory registrations, and commercial infrastructure continue to influence competition through their integration into Elanco and subsequent portfolio development.

C. H. Boehringer Sohn AG & Co. KG

Headquarters: Ingelheim am Rhein, Germany. C. H. Boehringer Sohn AG & Co.

KG is the parent organization associated with Boehringer Ingelheim, a family-owned pharmaceutical group founded in 1885. Its animal health business serves customers in more than 150 markets and holds strong positions in vaccines, parasiticides, therapeutics, and disease-prevention products. The 2017 integration of Merial substantially enlarged its companion-animal and livestock portfolio. Boehringer Ingelheim supports dogs, cats, horses, cattle, swine, poultry, and other species through medicines and preventive solutions. Major capabilities include canine parasiticides, swine vaccines, poultry health, and livestock disease control. Its long-term ownership structure allows sustained investment in research, manufacturing, biological development, and international veterinary partnerships across multiple animal health market segments.

Heska Corporation

Headquarters: Loveland, Colorado,

United States, before full integration. Heska Corporation specialized in veterinary diagnostic and specialty products for companion-animal practices. Its portfolio included chemistry analyzers, hematology systems, immunodiagnostics, imaging equipment, allergy testing, and practice-related technologies. The company built a presence across North America and selected European markets through internal development and acquisitions. Mars completed its acquisition of Heska in June 2023, and Heska became part of the Mars Petcare Science & Diagnostics division. It is therefore no longer an independent publicly traded animal health company. Its diagnostic technologies complement broader laboratory and veterinary-service capabilities within Mars. Heska’s market importance reflects the growing adoption of in-clinic testing, where results can be generated within minutes to support faster treatment decisions.

Bioniche Animal Health Canada, Inc.

Headquarters: Belleville, Ontario, Canada, during its independent operating period. Bioniche Animal Health

Canada developed veterinary pharmaceutical and biological products for livestock and companion animals. Its activities included reproductive health products, therapeutics, vaccines, and specialized technologies used by veterinarians and producers. Bioniche operated for several decades and established sales relationships across Canada, the United States, Australia, and selected international markets. In 2014, Vétoquinol acquired Bioniche’s animal health operations, integrating products, employees, regulatory registrations, and commercial infrastructure into its international organization. Bioniche Animal Health Canada therefore represents a legacy company rather than a current independent competitor. Its acquisition strengthened Vétoquinol’s presence in North America and added complementary products for cattle, horses, and companion animals to an established veterinary portfolio.

Cadila Healthcare Ltd.

Headquarters: Ahmedabad, Gujarat, India. Cadila Healthcare

changed its corporate name to Zydus Lifesciences in 2022. Through its animal health subsidiaries, the company developed pharmaceuticals, vaccines, feed supplements, and therapeutic products for cattle, poultry, companion animals, and other species. Its established-markets animal health undertaking became one of India’s leading veterinary businesses, supported by broad rural distribution and relationships with veterinarians and livestock producers. In 2021, the company agreed to sell this domestic-focused undertaking to an investor consortium. Zydus retained selected animal health interests connected with certain international markets. Cadila’s historical position demonstrates the importance of affordable medicines, extensive distribution, and livestock-focused portfolios in India, where more than 300 million cattle and buffalo create substantial demand for disease prevention and productivity support.

Conclusion

The top companies in the animal health market compete through pharmaceutical innovation, vaccine development, diagnostic technology, geographic distribution, manufacturing quality, and veterinary relationships. The competitive structure has changed significantly through major transactions completed in 2015, 2017, 2020, 2021, and 2023. Bayer Animal Health, Merial, Novartis Animal Health, Heska Corporation, and Bioniche Animal Health no longer operate as independent competitors, although their products and technologies remain active within acquiring organizations. Current market leadership increasingly depends on preventive medicine, companion-animal specialty care, livestock productivity, digital monitoring, and antimicrobial stewardship. With approximately 60% of known infectious diseases capable of animal-to-human transmission, animal health companies will remain essential contributors to food security, public health, veterinary care, and sustainable agriculture.